

119TH CONGRESS
2D SESSION

H. R. 7854

To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 5, 2026

Ms. TLAIB (for herself, Ms. LEE of Pennsylvania, and Mrs. CHERFILUS-McCORMICK) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Medicines for the Peo-
5 ple Act”.

1 **SEC. 2. ESTABLISHMENT.**

2 (a) IN GENERAL.—Part C of title IV of the Public
3 Health Service Act (42 U.S.C. 285 et seq.) is amended
4 by adding at the end the following:

5 **“Subpart 21—National Institute for Biomedical**
6 **Research and Development**

7 **“SEC. 464z-11. PURPOSE AND FUNCTIONS OF INSTITUTE.**

8 “(a) IN GENERAL.—The general purposes of the Na-
9 tional Institute for Biomedical Research and Development
10 (referred to in this subpart as the ‘Institute’) are—

11 “(1) to engage in full-cycle development of
12 drugs, devices, and biological products to promote
13 long-term access to medicines, foster innovation, and
14 ensure prioritization of public health needs; and

15 “(2) to make such drugs, devices, and biological
16 products available to the public at equitable and ac-
17 cessible prices.

18 “(b) RESEARCH AND DEVELOPMENT PROGRAM.—

19 “(1) IN GENERAL.—The Director of the Insti-
20 tute (referred to in this subpart as the ‘Director’)
21 shall carry out a program for the research and de-
22 velopment of drugs, devices, and biological products
23 for approval, licensure, clearance, or authorization
24 under section 505, 510(k), 513(f)(2), or 515 of the
25 Federal Food, Drug, and Cosmetic Act or section
26 351 of this Act.

1 “(2) ACTIVITIES.—The Director shall carry out
2 the program described in paragraph (1) through—

3 “(A) managing direct research and devel-
4 opment at Federal laboratories of the National
5 Institutes of Health;

6 “(B) contracting with public or private en-
7 tities for research and development;

8 “(C) acquisition of research and develop-
9 ment, including technologies and related sci-
10 entific data, from public or private entities;

11 “(D) licensing of patents under subsection
12 (f);

13 “(E) establishment of separate facilities to
14 conduct the work of the Institute, including, at
15 the discretion of the Director, the construction
16 of facilities and the acquisition of land, for the
17 purposes of the establishment or operation of
18 the Institute;

19 “(F) sharing scientific data in a timely
20 manner for use by research communities and
21 Federal and State agencies;

22 “(G) coordinating the activities of the In-
23 stitute with related activities of the other agen-
24 cies of the National Institutes of Health and
25 with related activities of other Federal agencies;

1 “(H) conducting or sponsoring research
2 necessary to obtain approval from the Food and
3 Drug Administration, including clinical trials to
4 generate safety and effectiveness data and in-
5 formation;

6 “(I) conducting health technology assess-
7 ments in accordance with paragraph (3) for
8 drug, devices, and biological products the re-
9 search or development of which is conducted or
10 funded under this section;

11 “(J) carrying out any other activities nec-
12 essary for the successful commercialization of
13 drugs, devices, and biological products the re-
14 search or development of which is conducted or
15 funded under this section; and

16 “(K) implementing goals, priorities, objec-
17 tives, policies, and procedures established by the
18 Board.

19 “(3) REQUIREMENTS FOR HEALTH TECH-
20 NOLOGY ASSESSMENTS.—

21 “(A) IN GENERAL.—In conducting health
22 technology assessments of drugs, devices, and
23 biological products for purposes of paragraph
24 (2)(I), the Director shall ensure that such
25 health technology assessments—

1 “(i) are conducted in a formal, sys-
2 tematic, and transparent manner;

3 “(ii) use state-of-the-art methods to
4 consider the best available evidence;

5 “(iii) examine the direct, intended
6 consequences and indirect, unintended con-
7 sequences of the use of the applicable
8 drug, device, or biological product, as com-
9 pared to existing alternatives; and

10 “(iv) consider factors such as clinical
11 effectiveness, safety, costs and economic
12 implications, ethical, social, cultural and
13 legal issues, organizational and environ-
14 mental aspects, and implications for pa-
15 tients, relatives, caregivers, and the broad-
16 er public.

17 “(B) DEFINITION OF HEALTH TECH-
18 NOLOGY ASSESSMENT.—In this section, the
19 term ‘health technology assessment’ means a
20 multidisciplinary process that uses explicit
21 methods to determine the value of a drug, de-
22 vice, or biological product.

23 “(c) RESEARCH MONITORING; ACQUISITION.—

24 “(1) IN GENERAL.—The Director shall monitor
25 the results of research conducted or supported by

1 the National Institutes of Health and by other ap-
2 propriate public and private entities, such as the
3 Biomedical Advanced Research and Development
4 Authority of the Department of Health and Human
5 Services or the Walter Reed Pilot Bioproduction Fa-
6 cility of the Department of Defense, to identify in-
7 ventions that, if subjected to appropriate research
8 and development activities, may be suitable for ap-
9 proval, licensure, clearance, or authorization under
10 section 505, 510(k), 513(f)(2), or 515 of the Fed-
11 eral Food, Drug, and Cosmetic Act or section 351
12 of this Act as a drug, biological product, or device.

13 “(2) ACQUISITION.—Notwithstanding chapter
14 18 of title 35, United States Code, the Director may
15 acquire, and shall have the right of first refusal for,
16 the rights to an invention identified under paragraph
17 (1) that is the result of research conducted or sup-
18 ported by the National Institutes of Health.

19 “(d) PRIORITIZATION.—In allocating the resources of
20 the Institute, the Board shall establish priorities for re-
21 search and development that reflect the magnitude of the
22 potential public health impact, unmet needs in current
23 product development, and the potential for scientific
24 breakthrough.

25 “(e) TRANSPARENCY.—

1 “(1) IN GENERAL.—The Director shall ensure
2 that the Institute adheres to the highest standards
3 of transparency by—

4 “(A) sharing with researchers, manufac-
5 turers, and the public preclinical and clinical
6 trial data and data on costs in an open and
7 timely manner, which data—

8 “(i) shall include all safety and effec-
9 tiveness data and information that has
10 been submitted in an application to the
11 Food and Drug Administration, including
12 an application submitted under section 505
13 of the Federal Food, Drug, and Cosmetic
14 Act or section 351 of this Act; and

15 “(ii) shall be deidentified to protect
16 patient privacy, but may not otherwise be
17 withheld from disclosure on any basis;

18 “(B) making information regarding activi-
19 ties carried out by the Institute publicly avail-
20 able online, including—

21 “(i) information regarding research
22 and development that is receiving priority;

23 “(ii) all data developed in carrying out
24 research and development activities;

1 “(iii) summary findings made in car-
2 rying out such activities; and

3 “(iv) copies of all licensing agreements
4 and contracts entered into with public and
5 private entities; and

6 “(C) requiring any entity that conducts re-
7 search funded by the Institute—

8 “(i) to share scientific data generated
9 from such research not later than the ear-
10 lier of the date of the first associated pub-
11 lication or the end of the period of the
12 award of such funds;

13 “(ii) when selecting a repository, to
14 give priority to—

15 “(I) data repositories supported
16 by or affiliated with the National In-
17 stitutes of Health; and

18 “(II) data repositories that—

19 “(aa) assign datasets unique
20 persistent identifiers;

21 “(bb) provide free and easy
22 access to datasets and their
23 metadata;

1 “(cc) make datasets and
2 metadata available for broad
3 reuse;

4 “(dd) have capabilities for
5 ensuring confidentiality for sen-
6 sitive data;

7 “(ee) have documented secu-
8 rity and integrity measures; and

9 “(ff) have documented pro-
10 cedures to restrict dataset access
11 and use that are consistent with
12 participant consent and changes
13 in consent, in the case of human
14 participant data;

15 “(iii) to take reasonable steps to en-
16 sure data is made available for as long as
17 such data may be useful for the larger re-
18 search community, institutions, or the pub-
19 lic; and

20 “(iv) on acceptance for publication
21 and consistent with applicable copyright
22 law, to submit, or have submitted on their
23 behalf, to the PubMed Central database of
24 the National Library of Medicine (or any
25 successor archive or database), an elec-

1 tronic version of the final, peer-reviewed
2 manuscript describing such research, which
3 manuscript shall be made publicly available
4 by the National Library of Medicine not
5 later than 1 year after the date on which
6 such manuscript is officially published.

7 “(2) DEFINITION OF SCIENTIFIC DATA.—In
8 this subsection, the term ‘scientific data’ means data
9 commonly accepted in the scientific community as of
10 sufficient quality to validate and replicate research
11 findings, regardless of whether the data are used to
12 support scholarly publications.

13 “(f) PATENTS AND TRADE SECRETS.—

14 “(1) IN GENERAL.—Notwithstanding chapter
15 18 of title 35, United States Code, the Director shall
16 ensure that the Federal Government owns the rights
17 to any patents and trade secrets relating to drugs,
18 devices, and biological products the research or de-
19 velopment of which is conducted or funded under
20 this section, including any research or development
21 conducted through contracting with a private entity
22 or acquired from a private entity under this section.

23 “(2) MANAGEMENT.—The Director shall man-
24 age the patents and trade secrets relating to re-

1 search and development conducted or funded under
2 this section in the public interest.

3 “(3) PATENTS.—

4 “(A) IN GENERAL.—The Director shall ob-
5 tain patents, as appropriate, for inventions re-
6 sulting from research and development con-
7 ducted or funded under this section.

8 “(B) STANDARD PATENT LICENSING POL-
9 ICY.—Unless otherwise determined by the Di-
10 rector, patents held by the Institute shall be li-
11 censed to the Medicines Patent Pool.

12 “(C) ACCESS.—Notwithstanding chapter
13 18 of title 35, United States Code, the Director
14 shall ensure public interest access, in terms of
15 both price and supply, considered independ-
16 ently, including in low- and middle-income
17 country markets, to patents and trade secrets
18 relating to drugs, devices, and biological prod-
19 ucts the research or development of which is
20 conducted or funded under this section, includ-
21 ing through—

22 “(i) stipulating, as a condition of re-
23 ceipt of Federal extramural biomedical re-
24 search funding awarded through the De-
25 partment of Health and Human Services,

1 that the Institute shall be granted rights to
2 all the data and technical information de-
3 veloped under a contract, including all nec-
4 essary intellectual property, technology,
5 know-how, and other information (includ-
6 ing master batch records, standard oper-
7 ating procedures, quality assurance and
8 quality control information, detailed bill of
9 materials for the drug, device, or biological
10 product and other manufacturing docu-
11 mentation) relating to the drug, device, or
12 biological product necessary for
13 operationalizing technology transfer;

14 “(ii) at the discretion of the Director,
15 stipulating in any contract the Institute
16 enters into with an extramural party that
17 such party will provide commercially rea-
18 sonable support for technology transfer ac-
19 tivities; and

20 “(iii) non-exclusive licensing to public,
21 nonprofit, and for-profit entities under
22 subparagraph (D).

23 “(D) LICENSING.—In any license of the
24 rights to a patent held by the Institute, the Di-
25 rector shall license patents—

1 “(i) to public entities, free of cost;

2 “(ii) to nonprofit organizations, free
3 of cost; and

4 “(iii) to for-profit entities with terms
5 that protect the public interest, including
6 non-exclusivity provisions, cost-plus pricing
7 terms, and reciprocity rules.

8 “(4) TRADE SECRETS AND CONFIDENTIAL COM-
9 Mercial INFORMATION.—

10 “(A) IN GENERAL.—The Director may not
11 claim trade secrets or confidential commercial
12 information with respect to any drugs, devices,
13 or biological products the research or develop-
14 ment of which is conducted or funded under
15 this section, including any research or develop-
16 ment conducted through contracting with a pri-
17 vate entity or acquired from a private entity
18 under this section.

19 “(B) CONFIDENTIAL COMMERCIAL INFOR-
20 MATION DEFINED.—In this paragraph, the term
21 ‘confidential commercial information’ means in-
22 formation that contains material exempt from
23 disclosure under subsection (b)(4) of section
24 552 of title 5, United States Code (commonly
25 known as the ‘Freedom of Information Act’).

1 “(g) PUBLIC AND PRIVATE MANUFACTURING; LI-
2 CENSING; ROYALTIES.—

3 “(1) IN GENERAL.—With respect to a drug, bi-
4 ological product, or device the patent for which is
5 held by the Federal Government under this section
6 and that is approved, licensed, cleared, or authorized
7 under section 505, 510(k), 513(f)(2), or 515 of the
8 Federal Food, Drug, and Cosmetic Act or section
9 351 of this Act, the Director shall provide for—

10 “(A) the public manufacturing of such
11 drug, biological product, or device, if prac-
12 ticable; and

13 “(B) such drugs, biological products, and
14 devices so manufactured to be sold at cost.

15 “(2) LICENSING; ROYALTIES.—If the Director
16 determines that public manufacturing for a drug, bi-
17 ological product, or device described in paragraph
18 (1) is not practicable, the Director—

19 “(A) may license the patent for such drug,
20 biological product, or device to a private entity,
21 based on the value established by a health tech-
22 nology assessment conducted under subsection
23 (b)(2)(I);

24 “(B) shall give preference to the manufac-
25 turing of such drug, biological product, or de-

1 vice, by a nonprofit organization before seeking
2 any manufacturing by for-profit companies;

3 “(C) shall, consistent with section 14 of
4 the Stevenson-Wydler Technology Innovation
5 Act of 1980, reinvest the royalties received from
6 such licensing into research and development
7 under this section; and

8 “(D) may consider the need for diversified,
9 regional production of medicines to ensure ac-
10 cess, or for other purposes, when granting li-
11 censes.

12 “(h) SUPERVISION.—The work of the Director shall
13 be directed and supervised by the Secretary, who shall
14 have the authority, after consulting with the voting mem-
15 bers of the Board, to remove the Director.

16 “(i) USE OF EXISTING RESOURCES.—In providing
17 for the establishment and operations of the Institute, the
18 Director of NIH may, on request of the Director of the
19 Institute—

20 “(1) transfer to the Institute such personnel of
21 the National Institutes of Health as the Director of
22 NIH determines to be appropriate;

23 “(2) allow the Institute to use such facilities of
24 the National Institutes of Health as the Director of
25 NIH determines to be appropriate; and

1 “(3) obtain administrative support for the Insti-
2 tute from the other agencies of the National Insti-
3 tutes of Health, including the other national re-
4 search institutes.

5 **“SEC. 464z-12. GOVERNING BOARD.**

6 “(a) IN GENERAL.—Not later than 180 days after
7 the date of enactment of the Medicines for the People Act,
8 the Secretary shall establish a governing board (referred
9 to in this subpart as the ‘Board’) to assist the Secretary
10 in establishing high-level policy, conducting long-term
11 planning, and providing overall direction for the Institute.

12 “(b) MEMBERSHIP.—

13 “(1) IN GENERAL.—The Board shall consist of
14 15 voting members, to be appointed by the Sec-
15 retary, including—

16 “(A) not fewer than 2 civil society rep-
17 resentatives with a background in identifying
18 and addressing barriers to the ability of individ-
19 uals and populations to acquire medicines need-
20 ed to achieve health;

21 “(B) not fewer than 2 patient advocates
22 from independent patient organizations that
23 take no funding from for-profit companies (or
24 foundations or nonprofit organizations affiliated
25 with for-profit companies) involved in the pro-

1 duction or sale of any drug, biological product,
2 or device and do not have executives from such
3 companies (or affiliated foundations or non-
4 profit organizations) on their governing boards;

5 “(C) not fewer than 2 current or former
6 public health officials;

7 “(D) not fewer than 2 current or former
8 members of the Institute, except in the case of
9 the initial membership of the Board; and

10 “(E) such other members as the Secretary
11 determines appropriate.

12 “(2) CHAIR.—The members of the Board shall
13 elect from among such members a Chair of the
14 Board.

15 “(3) NONVOTING MEMBERS.—The Secretary
16 may, after consulting with the voting members of
17 the Board, appoint not more than 4 nonvoting mem-
18 bers of the Board. Such nonvoting members shall
19 have relevant experience or expertise not already
20 represented on the Board.

21 “(4) TERMS.—

22 “(A) MEMBERS.—The term of each mem-
23 ber of the Board shall be not more than 6
24 years, and the Secretary shall designate stag-
25 gered terms for the members first appointed.

1 Members may serve 1 additional term at the
2 discretion of the Secretary.

3 “(B) CHAIR.—The term of the position of
4 Chair of the Board shall not exceed 6 years.

5 “(5) LIMITATIONS.—In appointing members
6 under paragraph (1), the Secretary shall ensure
7 that—

8 “(A) not more than 5 members are from
9 the for-profit sector;

10 “(B) no member is, or has been during the
11 6-year period preceding the date of appoint-
12 ment, a lobbyist, as defined in section 3 of the
13 Lobbying Disclosure Act of 1995, registered
14 under section 4 of that Act for a for-profit
15 pharmaceutical manufacturer;

16 “(C) no member is a current or former
17 senior executive officer of a covered entity;

18 “(D) no member is a current or former
19 senior executive officer of a covered entity dur-
20 ing the 6-year period beginning on the later
21 of—

22 “(i) the date of a Federal settlement
23 relating to a violation of sections 3729
24 through 3733 of title 31, United States
25 Code (commonly known as the ‘False

1 Claims Act'), the Federal Food, Drug, and
2 Cosmetic Act, including a Federal consent
3 decree, the Sherman Act, the Clayton Act,
4 or the Federal Trade Commission Act that
5 was entered into by the relevant covered
6 entity; and

7 “(ii) the date on which an enforce-
8 ment action relating to a violation by the
9 covered entity of sections 3729 through
10 3733 of title 31, United States Code (com-
11 monly known as the ‘False Claims Act’),
12 the Federal Food, Drug, and Cosmetic
13 Act, the Sherman Act, the Clayton Act, or
14 the Federal Trade Commission Act in a
15 court of the United States or by an Execu-
16 tive agency has concluded; and

17 “(E) no member during the time period
18 described in paragraph (6), with the intent to
19 influence or with the intent to gain information
20 for use in analyzing securities or commodities
21 markets or in informing investment decisions in
22 any securities or commodities market of the
23 United States, makes any communication to or
24 appearance before the former public office or
25 Executive agency of the member for compensa-

tion, provided that any such violation shall be subject to the penalties set forth in section 216 of title 18, United States Code.

“(6) TIME PERIOD.—The time period described in this paragraph is as follows:

“(A) With respect to an officer or employee of an Executive agency, the later of—

“(i) the date on which a President other than the President serving at the time of the termination of service or employment of the officer or employee takes office; and

“(ii) the date on which the 2-year period beginning on the date of the termination of service or employment as an officer or employee expires.

“(B) With respect to an officer or employee of an Executive agency who becomes a corporate lobbyist, the later of—

“(i) the date on which a President other than the President serving at the time of the termination of service or employment of the officer or employee takes office; and

1 “(ii) the date on which the 6-year pe-
2 riod beginning on the date of the termi-
3 nation of service or employment as an offi-
4 cer or employee expires.

5 “(c) DUTIES.—The Board, subject to the supervision
6 of the Secretary under subsection (e), shall—

7 “(1) establish goals, priorities, objectives, poli-
8 cies, and procedures relating to the operation and
9 development of the Institute, including identifying
10 promising inventions under subsection (c)(1) of sec-
11 tion 464z–11;

12 “(2) ensure that the Institute effectively carries
13 out the purposes specified in section 464z–11(a), in-
14 cluding that drugs, devices, or biological products
15 the research or development of which is conducted or
16 funded under section 464z–11 are successfully com-
17 mercialized and available to the public;

18 “(3) establish such committees or bodies as
19 may be necessary to facilitate or carry out the duties
20 of the Board; and

21 “(4) perform such other duties and responsibil-
22 ities as may be necessary to carry out this section.

23 “(d) DEFINITIONS.—In this section:

24 “(1) CORPORATE LOBBYIST.—The term ‘cor-
25 porate lobbyist’ means a lobbyist, as defined in sec-

1 tion 3 of the Lobbying Disclosure Act of 1995, who
2 is registered under section 4 of that Act and who is
3 employed by a corporation, as defined in section
4 101(9) of title 11, United States Code.

5 “(2) COVERED ENTITY.—The term ‘covered en-
6 tity’ means any entity that is—

7 “(A)(i) a for-profit company; or

8 “(ii) a bank holding company, a savings
9 and loan holding company, or any other finan-
10 cial institution; and

11 “(B)(i) operating under a Federal settle-
12 ment relating to a violation of sections 3729
13 through 3733 of title 31, United States Code
14 (commonly known as the ‘False Claims Act’),
15 the Federal Food, Drug, and Cosmetic Act, in-
16 cluding a Federal consent decree, the Sherman
17 Act, the Clayton Act, or the Federal Trade
18 Commission Act; or

19 “(ii) the subject of an enforcement action
20 relating to a violation of sections 3729 through
21 3733 of title 31, United States Code (commonly
22 known as the ‘False Claims Act’), the Federal
23 Food, Drug, and Cosmetic Act, the Sherman
24 Act, the Clayton Act, or the Federal Trade

1 Commission Act in a court of the United States
2 or by an Executive agency.

3 “(3) EXECUTIVE AGENCY.—The term ‘Execu-
4 tive agency’—

5 “(A) has the meaning given the term in
6 section 105 of title 5, United States Code; and

7 “(B) includes—

8 “(i) the Executive Office of the Presi-
9 dent and all components thereof, including
10 the White House Office; and

11 “(ii) the Office of the Vice President.

12 “(4) RIGHTS TO AN INVENTION.—The term
13 ‘rights to an invention’ includes all rights, title, and
14 interests in an invention, including—

15 “(A) any sale, assignment, or other trans-
16 fer of a patent on the invention, United States
17 or foreign; and

18 “(B) any exclusive license to a patent on
19 an invention, United States or foreign.

20 “(e) SUPERVISION.—The work of the Board shall be
21 directed and supervised by the Secretary who shall—

22 “(1) consult with the Board;

23 “(2) have the authority to review, approve,
24 modify, or reject any decision the Board makes pur-

1 suant to the duties of the Board under subsection
2 (c); and

3 “(3) make public any reasons why the Sec-
4 retary rejected or materially modified the decisions
5 of the Board pertaining to such duties.

6 “(f) POWERS.—

7 “(1) HEARINGS AND SESSIONS.—The Board
8 may, for the purpose of carrying out this section,
9 hold hearings, sit and act at times and places, take
10 testimony, administer oaths or affirmations to wit-
11 nesses appearing before the Board, and receive evi-
12 dence as the Board considers appropriate.

13 “(2) OBTAINING OFFICIAL DATA.—The Board
14 may secure directly from any department or agency
15 of the United States information necessary to enable
16 the Board to carry out the duties of the Board
17 under this section.

18 “(3) ADMINISTRATIVE SUPPORT SERVICES.—On
19 request of the Board, the Administrator of the Gen-
20 eral Services Administration shall provide to the
21 Board, on a reimbursable basis, the administrative
22 support services necessary for the Board to carry
23 out the duties of the Board under this section.

24 “(4) STAFF.—On request of the Board and on
25 a reimbursable basis, for the purpose of assisting the

1 Board in carrying out the duties of the Board, the
2 Secretary may detail to the Board any personnel of
3 their department.

4 “(g) TERMS OF OFFICE.—

5 “(1) VACANCIES.—A member appointed by the
6 Secretary to fill a vacancy on the Board occurring
7 before the expiration of the term for which the pred-
8 ecessor of the member was appointed shall be ap-
9 pointed for the remainder of such term.

10 “(2) REMOVAL.—A member may be removed
11 from the Board by the Secretary only for ineffi-
12 ciency, neglect of duty, or malfeasance in office.

13 “(h) PAY.—

14 “(1) RATES OF PAY.—Members of the Board
15 shall each be entitled to receive the daily equivalent
16 of the annual rate of basic pay for level IV of the
17 Executive Schedule under section 5315 of title 5,
18 United States Code, for each day (including travel
19 time) during which such members are engaged in
20 the performance of duties of the Board.

21 “(2) PROHIBITION OF COMPENSATION OF FED-
22 ERAL EMPLOYEES.—Notwithstanding paragraph (1),
23 the members of the Board who are full-time officers
24 or employees of the United States for purposes of
25 title 5, United States Code, may not receive addi-

1 tional pay, allowances, or benefits by reason of their
2 service on the Board.

3 “(3) TRAVEL EXPENSES.—Each member shall
4 receive travel expenses, including per diem in lieu of
5 subsistence, in accordance with applicable provisions
6 of subchapter I of chapter 57 of title 5, United
7 States Code.

8 “(i) APPLICATION OF FEDERAL ADVISORY COM-
9 MITTEE ACT.—The Board shall be subject to chapter 10
10 of title 5, United States Code (commonly referred to as
11 the ‘Federal Advisory Committee Act’), except that section
12 1013(a)(2) of such title shall not apply.

13 **“SEC. 464z-13. EVALUATION; REPORTS.**

14 “(a) IN GENERAL.—Not later than 5 years after the
15 date of enactment of the Medicines for the People Act,
16 and annually thereafter, the Director shall evaluate the
17 activities of the Institute. Such evaluation shall include the
18 following metrics:

19 “(1) Number of applications or submissions
20 under section 505, 510(k), 513(f)(2), or 515 of the
21 Federal Food, Drug, and Cosmetic Act or section
22 351 of this Act.

23 “(2) Number of clinical trial data sets pub-
24 lished in the public domain.

1 “(3) Number of new drugs, biological products,
2 and devices developed or brought to market, directly
3 or indirectly.

4 “(4) Number of licenses acquired from public,
5 nonprofit, and for-profit entities.

6 “(5) Number of patents licensed, disaggregated
7 by public, nonprofit, or private entity.

8 “(6) Number of patents filed.

9 “(7) Number of patents purchased or acquired.

10 “(8) Estimated savings to public health care
11 programs due to the activities of the Institute.

12 “(b) ANNUAL REPORTS.—Not later than 5 years
13 after the date of enactment of the Medicines for the Peo-
14 ple Act, and annually thereafter, the Director shall submit
15 to Congress, and make publicly available, a report describ-
16 ing the results of the applicable annual evaluation carried
17 out under subsection (a), including, for patents licensed,
18 filed, purchased, or acquired, the patent application num-
19 bers, filing dates, names of licensees, dates of licenses, and
20 where license agreements may be found.

21 **“SEC. 464z-14. AUTHORIZATION OF APPROPRIATIONS.**

22 ““There is authorized to be appropriated to carry out
23 this subpart \$90,000,000,000 for fiscal year 2027, to re-
24 main available until expended.”.

25 (b) CONFORMING AMENDMENTS.—

1 (1) Section 401 of the Public Health Service
2 Act (42 U.S.C. 281) is amended—

3 (A) in subsection (b)—

4 (ii) by redesignating paragraph (25)
5 as paragraph (26); and

6 (iii) by inserting after paragraph (24)
7 the following:

8 “(25) The National Institute for Biomedical
9 Research and Development.”; and

10 (B) in subsection (d)(1), by striking “27”
11 and inserting “28”.

12 (2) Section 405 of the Public Health Service
13 Act (42 U.S.C. 284) is amended—

14 (A) in subsection (b)(2)(B)(ii), by inserting
15 “or governing board” after “advisory council”;
16 and

17 (B) in subsection (c)(3), by inserting “or
18 governing board” after “advisory council”.

19 (c) PENALTIES AND INJUNCTIONS.—Section 216 of
20 title 18, United States Code, is amended—

21 (1) in subsection (a), in the matter preceding
22 paragraph (1), by inserting “or section 464z–12 of
23 the Public Health Service Act” after “of this title”;

1 (2) in subsection (b), by inserting “or section
2 464z-12 of the Public Health Service Act” after “of
3 this title”; and

4 (3) in subsection (c), by inserting “or section
5 464z-12 of the Public Health Service Act” after “of
6 this title”.

○